Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TORL-5-700

PreclinicalSmall molecule

TTORL Biotherapeutics, LLC

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Histologically Confirmed Relapsed or Refractory B-Cell Non-Hodgkin LymphomaRecruiting

Histologically Confirmed Relapsed or Refractory B-Cell Non-Hodgkin LymphomaPreclinical

Recruiting

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Histologically Confirmed Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT07439653

Clinical

Trials by Indication[1]

Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma1 trial

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting·TTORL Biotherapeutics, LLC·Preclinical·NCT07439653·155 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TORL-5-700. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TORL-5-700 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TORL-5-700. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TORL Biotherapeutics, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTORL Biotherapeutics, LLC

Related News